Total
0
Shares
Invex Therapeutics up 123 per cent after ASX debut
Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Amplia Therapeutics (ATX) has signed a term sheet for a collaboration agreement with the Garvan Institute of Media Research in Sydney
  • The term sheet maps out a collaborative research and clinical development program to treat patients with pancreatic cancer using Amplia’s FAK inhibitor, AMP945
  • The collaboration will combine the Garvan Institute’s research strength in FAK biology and its extensive clinical research network, with Amplia’s proprietary FAK inhibitors and drug development capability
  • The final Collaboration Agreement is expected to be signed within 90 days
  • Amplia is up 3.85 per cent, trading at 27 cents

Amplia Therapeutics (ATX) has signed a term sheet for a collaboration agreement with the Garvan Institute of Media Research in Sydney.  

The term sheet maps out a collaborative research and clinical development program, focused on the use of Amplia’s FAK inhibitor, AMP945, to treat patients with pancreatic cancer.

The collaboration will initially look at new treatment regiments and patient selection strategies for Amplia’s clinical trials of AMP945 in pancreatic cancer patients later this year.

The collaboration will combine the Garvan Institute’s research strength in FAK biology and its extensive clinical research network with Amplia’s proprietary FAK inhibitors and drug development capability.

“The purpose of this collaboration is to optimise our planned clinical program for AMP945,” said Amplia’s CEO and Managing Director, Dr John Lambert.

“Clearly, Garvan’s team has an unsurpassed understanding of FAK biology and access to an extensive clinical network. By leveraging Garvan’s deep understanding of the different biological roles that FAK can play, we aim to optimise the design of our planned clinical trials, recruit the right pancreatic cancer patients and treat them in the right way, giving AMP945 the best chance for success.”

Professor Paul Timpson, Cancer Research Theme Leader at Garvan will be the lead scientist in the collaborative research program, after collaborating with Amplia for over a year.

The terms of the agreement are confidential but include future payments by Amplia to Garvan based on AMP945 achieving specified clinical, regulatory and commercial sales milestones.

The final Collaboration Agreement is expected to be signed within 90 days.

Amplia is up 3.85 per cent, trading at 27 cents at 1:20 pm AEDT.  

ATX by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) brings ColoSTAT trial to Queensland

" Proteomics International Laboratories (ASX:PIQ) to collaborate for world’s first endometriosis test

Proteomics International Laboratories (PIQ) has penned a research agreement to develop a non-invasive test for endometriosis.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating - The Market Herald

" ResApp Health (ASX:RAP) secures two deals to integrate its diagnostic test

ResApp Health (RAP) has secured two new agreements for its smartphone-based acute respiratory diagnostic test.
Paradigm Biopharmaceuticals (ASX:PAR) - Chairman & CEO, Paul Rennie - The Market Herald

" FDA requests further clarification from Paradigm Biopharmaceuticals (ASX:PAR)

The US Food and Drug Administration has requested further clarification from Paradigm Biopharmaceuticals (PAR) for its Investigational New Drug (IND) application.
Patrys (ASX:PAB) - CEO and Managing Director, Dr James Campbell - The Market Herald

" Patrys’ (ASX:PAB) clinical trials pushed back

Patrys’ (PAB) planned PAT-DX1 clinical trial will be postponed for up to six months due to global manufacturing and supply chain delays.